GSK forms bioelectronics with Alphabet

GSK will hold a majority of 55 percent in the group


Afp August 01, 2016
A GlaxoSmithKline logo is seen outside one of its building. PHOTO: REUTERS

LONDON: British drugs giant GlaxoSmithKline announced Monday that it will form a joint venture with Google's parent company Alphabet to research and develop so-called bioelectronic medicines.

GSK has agreed with Verily Life Sciences (formerly Google Life Sciences) to create a new company called Galvani Bioelectronics, it said in a statement.

Bioniks provides 'Iron Man' arm to Pakistani child

The venture will be headquartered in Britain and will receive a total investment of up to £540 million ($714 million, 640 million euros) over seven years.

GSK will hold a majority of 55 per cent in the group and Verily will have a 45 per cent stake.

"Bioelectronic medicine is a relatively new scientific field that aims to tackle a wide range of chronic diseases using miniaturised, implantable devices that can modify electrical signals that pass along nerves in the body, including irregular or altered impulses that occur in many illnesses," the statement added.

"GSK has been active in this field since 2012 and believes certain chronic conditions such as arthritis, diabetes and asthma could potentially be treated using these devices."

Thought-controlled prosthetic limbs possibly within reach, scientists say

Monday's announcement comes one week after GSK revealed plans to invest £275 million into three of its British manufacturing sites, shrugging off worries over economic fallout arising from Brexit.

That investment will be ploughed into facilities in Barnard Castle in northeastern England, Ware in the southeast, and Montrose in Scotland.

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ